Vector Surgical

Vector Surgical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vector Surgical is a commercial-stage medical device company focused on improving surgical oncology outcomes through its Tissue Orientation System. Its flagship products, MarginMarker and CorrectClips, are designed to standardize and secure the marking of excised tissue margins, thereby reducing re-excision rates and improving communication between the surgical team and pathologists. The company has established a product portfolio that addresses clinical needs in breast, head & neck, pancreatic, cutaneous, and soft tissue sarcoma surgeries. It operates a direct commercial model, targeting hospitals and surgeons with its devices and supporting evidence from physician testimonials and clinical research.

Oncology

Technology Platform

Integrated Tissue Orientation System comprising sterile marking inks (MarginMarker) and radiographic marker clips (CorrectClips) for secure, standardized intraoperative labeling of surgical specimen margins to guide pathology analysis.

Opportunities

Significant opportunity to reduce high re-excision rates in breast cancer lumpectomy, a major clinical and cost burden.
Expansion into other solid tumor surgeries (sarcoma, pancreatic, cutaneous) represents adjacent, high-value markets.
The shift towards value-based healthcare rewards technologies that improve surgical outcomes and reduce complications.

Risk Factors

Competition from entrenched, low-cost margin marking methods (sutures, generic inks) and other commercial systems.
Reimbursement challenges and the need to consistently demonstrate cost-effectiveness to hospital value analysis committees.
Dependence on surgeon adoption and changing clinical practices.

Competitive Landscape

Competes against simple, low-cost methods (sutures, non-sterile inks) and potentially other commercial tissue marking systems. Differentiation is based on system integration (ink + clips), clinical evidence of accuracy, and standardization. The market is fragmented, with Vector positioning itself as the premium, evidence-based standard.